Insulin-like Growth Factor Binding Protein-1 Detection in Preterm Labor: Evaluation of a Bedside Test

 

 Buy Article Permissions and Reprints

ABSTRACT

Phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) is secreted by decidual cells and may leak into cervical secretions during detachment of the fetal membrane. The aim of this study was to determine whether a rapid bedside test for phIGFBP-1 predicts preterm birth in women with preterm uterine contractions. This was a prospective study of pregnant women who sought medical care for symptoms of preterm labor. Cervical swabs were assayed for the presence of phIGFBP-1 by a rapid bedside test. Sixty-four patients were enrolled. Eleven of them (17%) delivered preterm (< 35 weeks). phIGFBP-1 in cervical secretions predicted preterm birth with a sensitivity of 72.7%, a specificity of 83.0%, a positive predictive value of 47.0%, and negative predictive value of 93.6%. Positive phIGFBP-1 bedside test in women with preterm uterine contractions may indicate a significant risk for subsequent preterm birth. The absence of phIGBP-1 is a reassuring sign that the likelihood of preterm birth is low.

REFERENCES

• 1 Copper R L, Goldenberg R L, Creasy R K et al.. A multicenter study of preterm birth weight and gestational age-specific neonatal mortality.  Am J Obstet Gynecol. 1993;  168 78-84
  CrossrefPubMedGoogle Scholar
• 2 Papiernik E, Bouyer J, Collin D, Winisdoerffer G, Dreyfus J. Precocious cervical ripening and preterm labor.  Obstet Gynecol. 1986;  67 238-242
  PubMedGoogle Scholar
• 3 Iams J D, Goldenberg R L, Meis P J et al.. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network.  N Engl J Med. 1996;  334 567-572
  CrossrefPubMedGoogle Scholar
• 4 Lockwood C J, Senyei A E, Dische M R et al.. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery.  N Engl J Med. 1991;  325 669-674
  CrossrefPubMedGoogle Scholar
• 5 Rutanen E M, Bohn H, Seppala M. Radioimmunoassay of placental protein 12: levels in amniotic fluid, cord blood, and serum of healthy adults, pregnant women, and patients with trophoblastic disease.  Am J Obstet Gynecol. 1982;  144 460-463
  PubMedGoogle Scholar
• 6 Frost R A, Tseng L. Insulin-like growth factor-binding protein-1 is phosphorylated by cultured human endometrial stromal cells and multiple protein kinases in vitro.  J Biol Chem. 1991;  266 18082-18088
  PubMedGoogle Scholar
• 7 Koistinen R, Angervo M, Leinonen P, Hakala T, Seppala M. Phosphorylation of insulin-like growth factor-binding protein-1 increases in human amniotic fluid and decidua from early to late pregnancy.  Clin Chim Acta. 1993;  215 189-199
  CrossrefPubMedGoogle Scholar
• 8 Rutanen E M, Karkkainen T, Lundqvist C et al.. Monoclonal antibodies to the 27-34K insulin-like growth factor binding protein.  Biochem Biophys Res Commun. 1988;  152 208-215
  CrossrefPubMedGoogle Scholar
• 9 Nuutila M, Hiilesmaa V, Karkkainen T, Ylikorkala O, Rutanen E M. Phosphorylated isoforms of insulin-like growth factor binding protein-1 in the cervix as a predictor of cervical ripeness.  Obstet Gynecol. 1999;  94 243-249
  CrossrefPubMedGoogle Scholar
• 10 Kekki M, Kurki T, Karkkainen T, Hiilesmaa V, Paavonen J, Rutanen E M. Insulin-like growth factor-binding protein-1 in cervical secretion as a predictor of preterm delivery.  Acta Obstet Gynecol Scand. 2001;  80 546-551
  CrossrefPubMedGoogle Scholar
• 11 Lembet A, Eroglu D, Ergin T et al.. New rapid bed-side test to predict preterm delivery: phosphorylated insulin-like growth factor binding protein-1 in cervical secretions.  Acta Obstet Gynecol Scand. 2002;  81 706-712
  CrossrefPubMedGoogle Scholar
• 12 Rutanen E M, Karkkainen T H, Lehtovirta J, Uotila J T, Hinkula M K, Hartikainen A L. Evaluation of a rapid strip test for insulin-like growth factor binding protein-1 in the diagnosis of ruptured fetal membranes.  Clin Chim Acta. 1996;  253 91-101
  CrossrefPubMedGoogle Scholar
• 13 Nageotte M P, Casal D, Senyei A E. Fetal fibronectin in patients at increased risk for premature birth.  Am J Obstet Gynecol. 1994;  170 20-25
  PubMedGoogle Scholar
• 14 Cherouny P H, Pankuch G A, Romero R et al.. Neutrophil attractant/activating peptide-1/interleukin-8: association with histologic chorioamnionitis, preterm delivery, and bioactive amniotic fluid leukoattractants.  Am J Obstet Gynecol. 1993;  169 1299-1303
  PubMedGoogle Scholar
• 15 Inglis S R, Jeremias J, Kuno K et al.. Detection of tumor necrosis factor-alpha, interleukin-6, and fetal fibronectin in the lower genital tract during pregnancy: relation to outcome.  Am J Obstet Gynecol. 1994;  171 5-10
  PubMedGoogle Scholar
• 16 Ascarelli M H, Morrison J C. Use of fetal fibronectin in clinical practice.  Obstet Gynecol Surv. 1997;  52 S1-12
  CrossrefPubMedGoogle Scholar
• 17 Hill W C. A guest editorial: where are we now in screening patients for preterm delivery?.  Obstet Gynecol Surv. 2002;  57 133-135
  CrossrefPubMedGoogle Scholar
• 18 Rutanen E M, Pekonen F, Karkkainen T. Measurement of insulin-like growth factor binding protein-1 in cervical/vaginal secretions: comparison with the ROM-check Membrane Immunoassay in the diagnosis of ruptured fetal membranes.  Clin Chim Acta. 1993;  214 73-81
  CrossrefPubMedGoogle Scholar

Shai E ElizurM.D. 

Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center

Tel-Hashomer, 52621, Israel